Femasys appoints Dr. Kenneth Eichenbaum to board of directors

Femasys Inc. (NASDAQ: FEMY) announced the appointment of Kenneth D. Eichenbaum, M.D., M.S.E., to its board of directors. Dr. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital.

Dr. Eichenbaum brings more than 20 years of experience evaluating biotechnology and medical device companies and advising investment firms. He completed a fellowship at Stanford University Medical Center and earned his M.D. from the Icahn School of Medicine at Mount Sinai, with additional degrees in engineering from the University of Pennsylvania and in finance from The Wharton School.

"As we continue advancing innovative solutions in women's health, Dr. Eichenbaum brings a unique combination of clinical and technical expertise, along with deep financial insight, that will be invaluable to Femasys," said Kathy Lee-Sepsick, founder and chief executive officer of Femasys.

Dr. Eichenbaum said, "Femasys is advancing innovative, non-surgical solutions designed to improve the patient experience while reducing cost and complexity in women's reproductive care. I look forward to working with the board and management team to support the company's continued growth and innovation."

The company also announced that Joshua Silverman will be departing from the board of directors. Femasys expressed appreciation for Silverman's capital markets perspective and strategic counsel during his tenure.

Femasys develops fertility and birth control products for women. The company's product portfolio includes FemaSeed intratubal insemination for fertility treatment, FemSperm sperm preparation products, and FemVue for fallopian tube assessment. The company's FemBloc permanent birth control product received regulatory approval in Europe, the UK, and New Zealand in 2025.

You May Also Be Interested In

• Innoviz Technologies adds ex-Rafael CEO to its board
• A2Z extends $20M share repurchase program through December 2026
• Corbus Pharmaceuticals names new chief medical officer